Tempus will use bioinformatics and machine learning to analyze molecular, phenotypic, therapeutic and outcomes data for hundreds of breast cancer patients. Tempus and U-M researchers will analyze this data alongside the university’s patient-derived biological models, which alert providers to the drugs that will prove most effective for individual patients.
This agreement marks U-M’s second collaboration with Tempus. The organizations partnered to bring U-M’s DNA-sequencing panel, MI-ONCOSEQ, to cancer patients across the country in October.
More articles on health IT:
House allocates $65M to modernize VA EHRs
Philips opens 1st innovation center in Russia
69% of organizations don’t routinely test security controls, survey finds
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
